Immunohistochemical parameters investigated within the RICOVER-60 trial (all: n = 506, without rituximab: n = 251, with rituximab: n = 255)
| . | Negative . | Positive . | Negative, n (%) . | Positive, n (%) . | Not available,* n (%) . |
|---|---|---|---|---|---|
| CD5 | 0% | 1%-100% | 378 (94.5) | 22 (5.5) | 106 (20.9) |
| Without rituximab | 190 (94.5) | 11 (5.5) | 50 (19.9) | ||
| With rituximab | 188 (94.5) | 11 (5.5) | 56 (22.0) | ||
| CD10 | 0% | 1%-100% | 270 (65.7) | 141 (34.3) | 95 (18.8) |
| Without rituximab | 131 (64.5) | 72 (35.5) | 48 (19.1) | ||
| With rituximab | 139 (66.8) | 69 (33.2) | 47 (18.4) | ||
| BCL2 | 0% | 1%-100% | 88 (20.8) | 335 (79.2) | 83 (16.4) |
| Without rituximab | 42 (20.1) | 167 (79.9) | 42 (16.7) | ||
| With rituximab | 46 (21.5) | 168 (78.5) | 41 (16.1) | ||
| BCL6 | 0%-25% | 26%-100% | 67 (18.6) | 293 (81.4) | 146 (28.9) |
| Without rituximab | 30 (16.8) | 149 (83.2) | 72 (28.7) | ||
| With rituximab | 37 (20.4) | 144 (79.6) | 74 (29.0) | ||
| HLA-DR | 0% | 1%-100% | 77 (18.4) | 341 (81.6) | 88 (17.4) |
| Without rituximab | 40 (19.5) | 165 (80.5) | 46 (18.3) | ||
| With rituximab | 37 (17.4) | 176 (82.6) | 42 (16.5) | ||
| IRF4/MUM1 | 0%-4% | 5%-100% | 74 (18.6) | 323 (81.4) | 109 (21.5) |
| Without rituximab | 35 (17.6) | 164 (82.4) | 52 (20.7) | ||
| With rituximab | 39 (19.7) | 159 (80.3) | 57 (22.4) | ||
| Ki-67 | 0%-75% | 76%-100% | 103 (26.7) | 283 (73.3) | 120 (23.7) |
| Without rituximab | 49 (25.5) | 143 (74.5) | 59 (23.5) | ||
| With rituximab | 54 (27.8) | 140 (72.2) | 61 (23.9) |
| . | Negative . | Positive . | Negative, n (%) . | Positive, n (%) . | Not available,* n (%) . |
|---|---|---|---|---|---|
| CD5 | 0% | 1%-100% | 378 (94.5) | 22 (5.5) | 106 (20.9) |
| Without rituximab | 190 (94.5) | 11 (5.5) | 50 (19.9) | ||
| With rituximab | 188 (94.5) | 11 (5.5) | 56 (22.0) | ||
| CD10 | 0% | 1%-100% | 270 (65.7) | 141 (34.3) | 95 (18.8) |
| Without rituximab | 131 (64.5) | 72 (35.5) | 48 (19.1) | ||
| With rituximab | 139 (66.8) | 69 (33.2) | 47 (18.4) | ||
| BCL2 | 0% | 1%-100% | 88 (20.8) | 335 (79.2) | 83 (16.4) |
| Without rituximab | 42 (20.1) | 167 (79.9) | 42 (16.7) | ||
| With rituximab | 46 (21.5) | 168 (78.5) | 41 (16.1) | ||
| BCL6 | 0%-25% | 26%-100% | 67 (18.6) | 293 (81.4) | 146 (28.9) |
| Without rituximab | 30 (16.8) | 149 (83.2) | 72 (28.7) | ||
| With rituximab | 37 (20.4) | 144 (79.6) | 74 (29.0) | ||
| HLA-DR | 0% | 1%-100% | 77 (18.4) | 341 (81.6) | 88 (17.4) |
| Without rituximab | 40 (19.5) | 165 (80.5) | 46 (18.3) | ||
| With rituximab | 37 (17.4) | 176 (82.6) | 42 (16.5) | ||
| IRF4/MUM1 | 0%-4% | 5%-100% | 74 (18.6) | 323 (81.4) | 109 (21.5) |
| Without rituximab | 35 (17.6) | 164 (82.4) | 52 (20.7) | ||
| With rituximab | 39 (19.7) | 159 (80.3) | 57 (22.4) | ||
| Ki-67 | 0%-75% | 76%-100% | 103 (26.7) | 283 (73.3) | 120 (23.7) |
| Without rituximab | 49 (25.5) | 143 (74.5) | 59 (23.5) | ||
| With rituximab | 54 (27.8) | 140 (72.2) | 61 (23.9) |
Not scored from 2 or 3 observers or no consensus.